Alivus Life Sciences
ALIVUSNSE

Alivus Life Sciences

₹1,067.2521.00 (2.01%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,016.25
Today’s high
1,077.75
52 week low
819.00
52 week high
1,225.10
Open price
1,020.00
Previous close
1,046.25
Live volume
1,46,145
Lower circuit
837.00
Upper circuit
1,255.50

Fundamentals

Market Cap
₹12,804Cr
ROE
17.59%
P/E Ratio(TTM)
23.55
EPS(TTM)
44.30
P/B Ratio
4.25
Dividend Yield
0.48%
Industry P/E
39.91
Book Value
245.68
Debt to Equity
0.02
Face Value
2

Financials

*All values are in Rs. Cr
No Graph Data To Display
Quarterly
Yearly

About

Alivus Life Sciences Limited (formerly Glenmark Life Sciences) is a leading developer and manufacturer of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs) in chronic therapeutic areas.;
MD/CEO
Yasir Rawjee
Founded in
2011
NSE symbol
ALIVUS
Industry

Shareholding Pattern

Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Promoters
74.91%
Retail And Others
12.88%
Mutual Funds
5.44%
Foreign Institutions
5.09%
Other Domestic Institutions
1.68%

Mutual Funds Invested (4)

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
Natco PharmaNATCOPHARM
₹1,083.15
-21.05 (1.91%)
L
    H
    19,771.9412.712.29
    ₹1,383.80
    +12.40 (0.90%)
    L
      H
      18,984.5340.335.4
      ₹635.20
      +3.25 (0.51%)
      L
        H
        15,658.2928.713.66
        ₹896.10
        +5.30 (0.59%)
        L
          H
          14,205.5833.082.16
          Livesquawk
          A fire at Alivus Life Sciences' API plant in Dahej injured three people. The company is investigating the cause, assessing damages, and has sufficient insurance.
          Livesquawk
          Alivus Life Sciences aims to conclude 1-2 CDMO projects by Q1 FY27. The company projects double-digit growth for FY28-29.
          Livesquawk
          Alivus Life Sciences' Solapur plant is expected to start operations by July. The plant targets 85-90% capacity utilization once operational.
          Livesquawk
          Alivus Life Sciences revised FY '26 CapEx guidance to INR 450 crores from INR 600 crores. INR 150 crores of the CapEx has been deferred to FY '27 as per the update.
          Livesquawk
          Alivus Life Sciences raises EBITDA margin guidance to 30-32% from 28-30%. Improvement driven by operational efficiencies and new product launches.
          2026
          22
          Jan
          Quarterly Result
          Release date
          2025
          6
          Nov
          Quarterly Result
          Release date

          1
          Sep
          Dividend
          Ex date
          ₹5.00
          per share

          For each share you hold, you will receive ₹5.00
          Dividend amount₹5.00 per share
          Dividend TypeFinal
          Ex Date1 Sep ‘25
          Record Date1 Sep ‘25
          Announcement date15 May ‘25
          1
          Aug
          Quarterly Result
          Release date

          15
          May
          Dividend
          Announced
          ₹5.00
          per share

          For each share you hold, you will receive ₹5.00
          Dividend amount₹5.00 per share
          Dividend TypeFinal
          Ex Date1 Sep ‘25
          Record Date1 Sep ‘25
          Announcement date15 May ‘25
          Events calendar
          View upcoming events in other stocks